Last reviewed · How we verify
Cryoprecipitate
At a glance
| Generic name | Cryoprecipitate |
|---|---|
| Sponsor | CSL Behring |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
- Ablation Compare With Surgery for Early Breast Cancer (NA)
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
- Cumulus Cell Mitochondrial Activity as a Non-invasive Marker of Embryo Quality (FLIM)
- Defining a Technique for the Use of Cryogenic Catheters for Biopsy and Ablation for the Diagnostic and Treatment of Pulmonary Lesions: An Ex-Vivo Human Lung Model Study. (NA)
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery (PHASE3)
- Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cryoprecipitate CI brief — competitive landscape report
- Cryoprecipitate updates RSS · CI watch RSS
- CSL Behring portfolio CI